Abstract 1368TiP
Background
Lung cancer represents a successful example of precision medicine application in medical oncology, since the introduction of routine molecular testing and targeted therapies into clinical practice has significantly contributed to decrease non-small cell lung cancer (NSCLC) patients’ mortality worldwide. International guidelines recommend the routine use of next generation sequencing (NGS) as new standard approach to profile advanced lung adenocarcinoma samples, with the aim of identifying targetable driver mutations that allow patients’ access to effective targeted drugs either available in daily practice or in the context of clinical trials. However, only a small proportion of advanced NSCLC patients currently undergo a complete molecular testing, because of high cost, reimbursement issues, as well as limited access to NGS-platforms across the different countries. At the same time, inequalities in access to new drugs and clinical trials in Europe is something that must be addressed and solved. To fill the gap affecting the relevant heterogeneity of molecular testing and cancer care across Europe, the Women Against Lung Cancer in Europe (WALCE) Association promoted the European Program for Routine testing of Patients with Advanced lung cancer (EPROPA).
Trial design
EPROPA provides a molecular screening platform for NSCLC samples characterization in order to increase the detection of common and rare oncogenic drivers and optimizing patients’ access to clinical trials. Centers that join EPROPA may share anonymized clinical-pathological data and ship tissue samples to the lab of the Reference Center (University of Turin) to perform molecular test to determine patients’ eligibility for personalized therapies or clinical trials. For patients candidates to clinical trials and a caregiver, logistic support will be provided during the phases of the diagnostic and therapeutic process. All patients over 18-years old, with histological/cytological diagnosis of NSCLC; stage IIIB/C-IV (8th TNM Staging System); with formalin fixed paraffin embedded tissue sample availability for molecular analysis can benefit from EPROPA whose aim is to contribute to the reduction of inequality in access to tests, drugs and clinical trials in Europe.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
WALCE.
Funding
Amgen, Blueprint Medicines, BeiGene, Roche, AZ, Merck, MSD, Lilly, Incyte, Pfizer.
Disclosure
F. Passiglia: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Amgen. M.L. Reale: Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim; Non-Financial Interests, Personal, Member of the Board of Directors: WALCE. S. Vallone: Non-Financial Interests, Personal, Member of the Board of Directors: WALCE. F. Arizio: Non-Financial Interests, Personal, Member of the Board of Directors: WALCE. N.M. Secen: Financial Interests, Personal, Full or part-time Employment: Institute for Pulmonary Diseases of Vojvodina. E. Felip: Financial Interests, Personal, Speaker’s Bureau: Amgen; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Bristol Myers SQUIBB; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: F. Hoffmann-La Roche; Financial Interests, Personal, Speaker’s Bureau: Janssen; Financial Interests, Personal, Speaker’s Bureau: Medscape; Financial Interests, Personal, Speaker’s Bureau: Merck Sharp & Dohme; Financial Interests, Personal, Speaker’s Bureau: Merck Serono; Financial Interests, Personal, Speaker’s Bureau: Peervoice; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Springer; Financial Interests, Personal, Speaker’s Bureau: Touch Medical; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Beigene; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: F. Hoffmann-La Roche; Financial Interests, Personal, Advisory Board: GlaxoSmithKline; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Advisory Role: Medical Trends; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Peptomyc; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Puma; Financial Interests, Personal, Advisory Board: Regeneron; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Advisory Board: Syneos Health; Financial Interests, Personal, Advisory Board: Takeda; Non-Financial Interests, Personal, Member of the Board of Directors: Grífols. A. Araújo: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Role: Astellas; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: Lilly; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Astellas. H. Linardou: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Amgen; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Sponsor/Funding: AstraZeneca; Financial Interests, Personal, Sponsor/Funding: Pfizer. L. Mazilu: Financial Interests, Personal, Advisory Board: Accord; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Bristol Mayer Squibb; Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Advisory Board: Johnson & Johnson Romania; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Role: Roche; Financial Interests, Personal, Advisory Board: Sandoz; Financial Interests, Personal, Speaker’s Bureau: Accord; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Astellas; Financial Interests, Personal, Speaker’s Bureau: Bayer; Financial Interests, Personal, Speaker’s Bureau: BMS; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Ipsen; Financial Interests, Personal, Speaker’s Bureau: Johnson & Johnson Romania; Financial Interests, Personal, Speaker’s Bureau: Merck; Financial Interests, Personal, Speaker’s Bureau: MSD; Financial Interests, Personal, Speaker’s Bureau: Novartis; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Personal, Speaker’s Bureau: Roche; Financial Interests, Personal, Speaker’s Bureau: Sandoz; Financial Interests, Personal, Speaker’s Bureau: Servier; Financial Interests, Institutional, Research Grant: Ovidius University of Constanta, Romania; Financial Interests, Personal, Sponsor/Funding: AstraZeneca; Financial Interests, Personal, Sponsor/Funding: BMS; Financial Interests, Personal, Sponsor/Funding: Eli Lilly; Financial Interests, Personal, Sponsor/Funding: MSD; Financial Interests, Personal, Sponsor/Funding: Novartis; Financial Interests, Personal, Sponsor/Funding: Pfizer; Financial Interests, Personal, Sponsor/Funding: Roche. E. Szmytke: Non-Financial Interests, Personal, Member of the Board of Directors: Lung Cancer in Europe; Non-Financial Interests, Personal, Leadership Role: Lung Cancer in Europe; Financial Interests, Institutional, Funding: AstraZeneca; Financial Interests, Institutional, Funding: Bayer; Financial Interests, Institutional, Funding: Blueprint Medicines; Financial Interests, Institutional, Funding: BMS; Financial Interests, Institutional, Funding: BI; Financial Interests, Institutional, Funding: Eli Lilly; Financial Interests, Institutional, Funding: Merck; Financial Interests, Institutional, Funding: MSD; Financial Interests, Institutional, Funding: Novartis; Financial Interests, Institutional, Funding: Pfizer; Financial Interests, Institutional, Funding: Takeda; Financial Interests, Institutional, Funding: Roche; Financial Interests, Institutional, Funding: Genzyme Corporation; Financial Interests, Institutional, Funding: Regeneron. A. Comanescu: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Novartis. G. Scagliotti: Financial Interests, Personal, Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Role: Beigene; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Institutional, Research Grant: Eli Lilly; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Tesaro; Financial Interests, Personal, Other: Bayer; Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Invited Speaker: Johnson & Johnson; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Takeda. S. Novello: Financial Interests, Personal, Invited Speaker: AZ; Financial Interests, Personal, Advisory Board: BI; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Invited Speaker: Eli Lilly; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Sanofi; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Beigene; Financial Interests, Institutional, Invited Speaker: MSD; Financial Interests, Institutional, Invited Speaker: BI. All other authors have declared no conflicts of interest.